+1 (800) 559-9921
Dear Fellow Scientists:
August was indeed a prolific month for MRMP! Our highlight is without contest the opening of our first laboratory in Europe: MRMP Europe.
We also launched MRMAssayDB and the Antibiotic Spotter, published so far 12 papers in 2024, proudly announced the climbing Impact Factor of the ERP journal, and added two new services for the community.
Scroll down to read more!
Highlights
Opening of MRMP Europe!
We are proud to announce the opening of our first laboratory in Europe (Rüsselsheim -Germany, close to Frankfurt), to serve the European market. The laboratory is focused on providing absolute quantitation of proteins and metabolites in clinical samples, with the assays developed both on site and in Montreal.
Need an extensive database? Search no more! We give you MRMAssayDB
Developed jointly between MRMP and the Segal Cancer Proteomics Centre/Warren Y. Soper Clinical Proteomics Centre, MRMAssayDB is our largest database (DB) for curated data on available and applied targeted proteomics assays in the community.
Our improved and extended version lists over 1.12 million assays and includes data on 940k stripped peptides
The database now covers 61k proteins from 146 organisms.
Additionally, projecting the peptide assay data on the incorporated AlphaFold protein structural predictions provides new insights into the assays and enhances the utility for proteomics research.
MRMAssayDB v3 will be available after publication free of charge, and early access to the data will be available via our bioinformatics team.
12 papers… and counting!
Together with Dr. Borchers’ lab and collaborators from LDI, McGill and other institutions, our services led to 12 papers published in 2024.
1. Proteomic evidence of depression-associated astrocytic dysfunction in the human male olfactory bulb.
2. Measurement of CYP1A2 and CYP3A4 activity by a simplified Geneva cocktail approach in a cohort of free-living individuals: a pilot study.
Find the rest of the publications by clicking the learn more link.
Antiobiotic Spotter: Why a MRM multiplex antibiotic assay?
- A multiplex antibiotic MRM assay for identifying and quantifying antibacterial (37) and antifungal (11) drugs suitable for therapeutic drug monitoring (TDM), Exposomics studies, and Environmental or Food Contamination Monitoring.
- Therapeutic Drug Monitoring helps optimize antibiotic treatment and enhances patient outcomes, especially in intensive care units (ICUs).
- Environmental and food contamination with antibiotics can largely influence antimicrobial resistance, and its monitoring can assess its risks and limit its impact
This assay is offered by MRMP and the Segal Cancer Proteomics Centre/Warren Y. Soper Clinical Proteomics Centre.
Huge jump in Impact Factor for Expert Review of Proteomics!
We are thrilled to share that Expert Review of Proteomics (ERP) has achieved a significant milestone with our latest impact factor increase to 3.8, jumping a full .4. Dr. René Zahedi and our CSO, Dr. Christoph Borchers, and the co-editors-in-chief of ERP would like to thank you, dear contributing authors. Your great research expertise and pursuit of excellence in science are the backbone of ERP. Together we are climbing the impact factor scale… to the top!
Two New Services!
MRM Proteomics has added two new services to our service profile.
1. Sensitive and robust proteomic analysis of low input sample types (FFPE, FACS, IP, etc.). > 5000 proteins quantifiable from < 50 ng of peptides using the Evosep-Whisper Zoom method.
2. Deep plasma proteomics using MagNet-based microparticle enrichment. > 4000 proteins quantifiable from plasma derived extracellular vesicles using Evosep/Bruker TimsTof system to perform DIA-PASEF.